Please ensure Javascript is enabled for purposes of website accessibility

Why This Under-the-Radar Stock Is a Buy

By Neil Patel - Mar 4, 2021 at 8:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It pays to keep an eye on areas of the market that most other investors overlook.

In an age when all market participants have access to the same information, gaining an edge can seem nearly impossible. But there is a way for smaller investors to secure an advantage: Look where others aren't. 

Seeking out under-the-radar stocks can be a winning strategy, because by definition these companies go unnoticed by the majority of investors. One such business is The Joint Corp. (JYNT -0.55%), a small-cap stock with a current market value of $636 million that should be on investors' watch lists. 

Here is why I think this stock is a buy.

A female doctor works with a female patient lifting her leg.

Image Source: Getty Images.

Making chiropractic care accessible 

The Joint Corp. operates 560 clinics in 33 states, and what separates the company from traditional chiropractic offices is the type of service provided and the cost. At an average of just $29 per visit, patients can receive a fast (in as little as five minutes) and effective spinal adjustment from a licensed chiropractor. Only walk-ins are accepted. And because it's a private-pay model, patients can get treatment without health insurance. 

The average Joint Corp. clinic can see more than 1,350 patients per month, compared to fewer than half that at a regular chiropractic office. The business has created an accessible and consumer-friendly setup that has attracted people new to this type of care. In a February 2019 new-patient survey, 26% of Joint Corp. users reported never having been to a chiropractor before. 

The Joint Corp. primarily operates with a membership-based revenue model. In 2019, an impressive 80% of systemwide sales came from monthly memberships. This should be music to investors' ears -- a recurring revenue stream is better than a transactional structure because it provides more visibility into the business and allows the company to maintain valuable relationships with its customers. 

A scalable business model 

In 2012, The Joint Corp. only had 82 locations (this is not a typo). How did the company grow so quickly? On the backs of other people's capital. It is a franchisor of its clinics, which explains how systemwide revenue skyrocketed from $8.1 million in 2012 to $220.3 million in 2019. Of the 560 locations as of Sept. 30, 497 were owned and operated by franchisees, with an additional 218 currently in development. 

But if you're a prospective shareholder of The Joint Corp., don't think you've missed out on the growth. Management believes that by the end of 2023, there will be 1,000 clinics nationwide. And over the long term, they see the potential for 1,800 locations in the U.S.  

Growing in this capital-light way will do wonders for The Joint Corp.'s bottom line over the next few years. The operating-income margin on the company's franchise segment was 46% in the first nine months of 2020, much higher than the 12% for corporate-owned clinics. So as more clinics are opened by franchisees, The Joint Corp.'s overall income should soar. 

Look where there's less competition 

Investing is hard, and the competition for market-beating returns is fierce. There are institutions out there with massive research budgets that focus most of their time and energy on the largest companies. This gives individual investors an advantage if they spend their efforts on smaller stocks. 

The Joint Corp. is a fantastic growth story, and it's not done climbing just yet. Although the stock has had quite the run-up recently, there is still plenty of room to go. Investors willing to do the work and look where others haven't should contemplate buying shares of this under-the-radar stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Joint Corp. Stock Quote
The Joint Corp.
JYNT
$16.37 (-0.55%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.